Taylor M J, Gregory R, Tomlins P, Jacob D, Hubble J, Sahota T S
Leicester School of Pharmacy, Faculty of Health and Life Sciences, De Montfort University, The Gateway, Leicester LE1 9BH, United Kingdom.
Department of Diabetes and Endocrinology, University Hospitals of Leicester NHS Trust, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, United Kingdom.
Int J Pharm. 2016 Mar 16;500(1-2):371-8. doi: 10.1016/j.ijpharm.2015.12.024. Epub 2015 Dec 12.
The performance of a completely implantable peritoneal artificial pancreas (AP) has been demonstrated in principle in a live diabetic domestic pig. The device consists of a smart glucose-sensitive gel that forms a gateway to an insulin reservoir and is designed to both sense glucose and deliver insulin in the peritoneal cavity. It can be refilled with insulin via subcutaneous ports and surgery was developed to insert the AP. Diabetes was induced with streptozotocin (STZ), the device filled with insulin (Humulin(®) R U-500) in situ and the animal observed for several weeks, during which time there was normal access to food and water and several oral glucose challenges. Blood glucose (BG) levels were brought down from >30 mmol/L (540 mg/dL) to non-fasted values between 7 and 13 mmol/L (126-234 mg/dL) about five days after filling the device. Glucose challenge responses improved ultimately so that, starting at 10 mmol/L (180 mg/dL), the BG peak was 18 mmol/L (324 mg/dL) and fell to 7 mmol/L (126 mg/dL) after 30 min, contrasting with intravenous attempts. The reservoir solution was removed after 8 days of blood glucose levels during which they had been increasingly better controlled. A rapid return to diabetic BG levels (30 mmol/L) occurred only after a further 24 days implying some insulin had remained in the device after removal of the reservoir solution. Thus, the closed loop system appeared to have particular influence on the basal and bolus needs for the 8 days in which the reservoir solution was in place and substantial impact for a further 3 weeks. No additional insulin manual adjustment was given during this period.
完全植入式腹膜人工胰腺(AP)的性能已在一只患有糖尿病的活体家猪身上得到了原理验证。该装置由一种智能葡萄糖敏感凝胶组成,它构成了通向胰岛素储存器的通道,旨在既能感知葡萄糖又能在腹腔内输送胰岛素。它可以通过皮下端口重新填充胰岛素,并且已经开发出手术方法来植入AP。用链脲佐菌素(STZ)诱导糖尿病,在原位将装置填充胰岛素(优泌林(®)R U - 500),并对动物观察数周,在此期间动物可以正常获取食物和水,并进行了几次口服葡萄糖耐量试验。在填充装置后约五天,血糖(BG)水平从>30 mmol/L(540 mg/dL)降至非空腹值7至13 mmol/L(126 - 234 mg/dL)。葡萄糖耐量试验反应最终得到改善,以至于从10 mmol/L(180 mg/dL)开始,BG峰值为18 mmol/L(324 mg/dL),并在30分钟后降至7 mmol/L(126 mg/dL),这与静脉注射试验形成对比。在血糖水平得到越来越好的控制的8天后,取出储存器溶液。仅在再过24天后血糖水平迅速恢复到糖尿病水平(30 mmol/L),这意味着在取出储存器溶液后仍有一些胰岛素留在装置中。因此,闭环系统在储存器溶液在位的8天内似乎对基础和推注胰岛素需求有特别影响,并且在另外3周内有显著影响。在此期间未进行额外的胰岛素手动调整。